AMRX Stock Analysis: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$11.93
-0.30 (-2.45%)
▼
5d:
-9.62%
30d:
-8.86%
90d:
-19.5%
HOLD
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 01, 2026
0d
Smart Money Accumulation
AMRX is down 9.6% this week, but smart money is accumulating calls. Top strike: $15 2026-06-18 with 382 OI. Call ratio: 100% View Scanner →
Strength: 9.8/10
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AMRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AMRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.46
Based on 11.4% avg growth
INTRINSIC VALUE TODAY
$15.81
24.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $11.93, which is considered oversold relative to its 30-day fair value range of $12.48 to $13.30. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.1) compared to its historical average (12.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This pessimistic expectation contrasts with the company's recent 384.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is currently testing key support at $11.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+42.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is currently testing key support at $11.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+42.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$12.48 -
$13.30
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding AMRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.5% below Wall St target ($17.00)
- CAUTION: Recommendation downgraded due to -9.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$12.48 -
$13.30
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$11.88
Resistance Level
$13.84
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.08
Wall Street Target
$17.00
(+42.5%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
384.6%
Profit Margin
4.0%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
10.1 vs 12.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$11.06
(-7%)
2-Year Target
$10.25
(-14%)
3-Year Target
$9.50
(-20%)
3-Yr Target (if PE normalizes)
(PE: 10→13)
$11.88
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 18.8%)
$43.79
(+267%)
Base:
(SPY PE: 10.1, Growth: 18.8%)
$19.99
(+68%)
Bear:
(PE: 8.6, Growth: 18.8%)
$16.99
(+42%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 33.05 | Current EPS (TTM): $0.37
Bull Case
$26.91
(+126%)
Analyst growth 100.0%, PE expands to 36.4
Base Case
$24.46
(+105%)
Market implied 100.0%, PE stable at 33.1
Bear Case
$8.32
(-30%)
Severe decline -20.0%, PE contracts to 28.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.1 to 12.6
Stabilization Target:
$14.92
(+25.1%)
PE Expansion Potential:
+25.1%
Share & Embed Analysis
Last updated: May 18, 2026 9:35 AM ET
Data refreshes hourly during market hours. Next update: 10:35 AM
Data refreshes hourly during market hours. Next update: 10:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
